


PHARMACEUTICAL 2022

Eliem Therapeutics Inc. Rank 50 of 466





PHARMACEUTICAL 2022



Eliem Therapeutics Inc. Rank 50 of 466

The relative strengths and weaknesses of Eliem Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eliem Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Eliem Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 268%, being 190% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	148,252
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,031
Liabilities, Non-Current	7.0
Other Assets	24,989
Other Compr. Net Income	0
Other Expenses	1,276
Other Liabilities	0
Other Net Income	-11,808
Other Revenues	0
Property and Equipment	0
Research and Development	22,046
Selling, General and Administrative Expense	12,350

Output Variable	Value in 1000 USD
Assets	173,241
Liabilities	6,038
Expenses	35,672
Revenues	0
Stockholders Equity	167,203
Net Income	-47,480
Comprehensive Net Income	-47,480
Economic Capital Ratio	268%

